Johnson & Johnson Form 4 insider transactions

Mark A. Weinberger, an insider at Johnson & Johnson, acquired 1,000 shares of common stock at a price of $147.22 per share on December 12, 2024.

Eugene A. Woods, a director at Johnson & Johnson, acquired deferred share units (DSUs) as part of his director compensation.

Director Marillyn A. Hewson acquired deferred share units (DSUs) of Johnson & Johnson, representing a deferral of cash retainer under the company's Amended and Restated Deferred Fee Plan for Directors.

John C. Reed, EVP of Innovative Medicine R&D at Johnson & Johnson, amended a Form 4 filing to correct the total number of shares transacted and the number of securities beneficially owned following a transaction on May 1, 2024.

Executive VP and CFO of Johnson & Johnson, Joseph J. Wolk, reports changes in beneficial ownership of company stock through gifts and holdings in a spousal lifetime access trust and 401k.

Director D. Scott Davis acquired 1,385.697 Deferred Share Units (DSUs) in Johnson & Johnson on April 25, 2024, under the company's Amended and Restated Deferred Fee Plan for Directors.

Eugene A. Woods, a director at Johnson & Johnson, acquired deferred share units (DSUs) representing the deferral of cash retainer under the company's Amended and Restated Deferred Fee Plan for Directors.

Director Marillyn A. Hewson reports acquisition of Deferred Share Units (DSUs) related to deferred cash retainer under Johnson & Johnson's director fee plan.

Robert J. Decker, VP Corporate Controller at Johnson & Johnson, exercised stock options and sold shares on August 30, 2024.

EVP Vanessa Broadhurst reports acquisition of shares through vesting of restricted stock units and subsequent disposal for tax obligations.

Eugene A. Woods, a director at Johnson & Johnson, acquired deferred share units (DSUs) as part of the company's Amended and Restated Deferred Fee Plan for Directors.

Director Marillyn A. Hewson acquired deferred share units (DSUs) of Johnson & Johnson on June 4, 2024, under the company's Amended and Restated Deferred Fee Plan for Directors.

EVP John C. Reed of Johnson & Johnson reports the vesting of restricted share units and subsequent tax withholding.

Mary C. Beckerle, a director at Johnson & Johnson, acquired deferred share units under the company's Amended and Restated Deferred Fee Plan for Directors.

Director Marillyn A. Hewson reports the acquisition of deferred share units in Johnson & Johnson, to be settled in cash upon termination of directorship.

Director Nadja West reports acquisition of deferred share units in Johnson & Johnson under the company's Amended and Restated Deferred Fee Plan for Directors.

Director Darius Adamczyk receives deferred share units under Johnson & Johnson's Amended and Restated Deferred Fee Plan for Directors.

Director Eugene A. Woods reported the acquisition of deferred share units in Johnson & Johnson, to be settled in cash upon termination of directorship.

Director Anne M. Mulcahy reports the acquisition of deferred share units in Johnson & Johnson, to be settled in cash upon termination of directorship.

Mark B. McClellan, a director at Johnson & Johnson, acquired deferred share units under the company's Amended and Restated Deferred Fee Plan for Directors.

Mark A. Weinberger, a director at Johnson & Johnson, acquired deferred share units under the company's Amended and Restated Deferred Fee Plan for Directors.

Director Hubert Joly reports acquisition of deferred share units in Johnson & Johnson under the company's Amended and Restated Deferred Fee Plan for Directors.

Director Paula A. Johnson acquired deferred share units in Johnson & Johnson under the company's Amended and Restated Deferred Fee Plan for Directors.

Director Jennifer A. Doudna reports the acquisition of deferred share units in Johnson & Johnson, to be settled in cash upon termination of directorship.

EVP Vanessa Broadhurst sold 8,891 shares of Johnson & Johnson common stock at an average price of $162.16 on March 13, 2024.

Director Eugene A. Woods reports acquisition of deferred share units in Johnson & Johnson under the company's Amended and Restated Deferred Fee Plan for Directors.

Director Marillyn A. Hewson acquired deferred share units (DSUs) of Johnson & Johnson related to director fees.

Johnson & Johnson reports transactions involving CVRx, Inc. common stock and derivative securities, including warrant exercises and stock option acquisitions, through its subsidiary Johnson & Johnson Innovation JJDC, Inc.